Children's Research Institute

Children's Research Institute, doing business as Childrens Research Institute, is a tax-exempt nonprofit pediatric research organization based in Washington, DC that serves as a grant recipient and contract awardee for federal biomedical and clinical research across the National Institutes of Health and other federal health agencies. The organization operates as the research subsidiary of Children's National Medical Center, its parent entity, and focuses on investigator-initiated research and clinical trials addressing pediatric health conditions spanning neuroscience, oncology, immunology, rare diseases, and cardiac and pulmonary medicine.

Children's Research Institute's portfolio centers on federal grant funding, with 679 total awards across prime and sub roles (64% prime, 36% sub). The National Institute of Child Health and Human Development (NICHD) is the dominant funder by dollar value, with 65 awards worth $12.5 million combined potential value, followed by the National Heart Lung and Blood Institute (NHBLI) with 59 awards totaling $8.5 million. The National Institute of Neurological Disorders and Stroke, National Cancer Institute, and National Institute of Diabetes and Digestive and Kidney Diseases each support substantial research portfolios at the institute. Together, these five National Institutes account for roughly 46% of recent awards by count and approximately 82% of combined potential value. The institute receives no contract vehicles; its federal relationship is entirely grant-based through NIH project grants, cooperative agreements, and research training programs.

Recent activity reflects consistent grant capture across FY2022–FY2026, with 45 awards in 2022 growing to 98 awards in 2024, then moderating to 78 in 2025 and 22 recorded through mid-2026. The organization faces 56 awards (combined potential value $4.2 million) with ultimate completion dates in the next twenty-four months, representing recompete exposure for principal investigators and labs across neurodevelopmental disorders, neurological disease, cancer immunotherapy, cardiac and metabolic conditions, and rare genetic syndromes.

Representative grant work spans pediatric neuroscience, translational medicine, and clinical trials. NICHD has funded longitudinal studies on maternal depression and fetal brain development (FABMOMS, $794,699), Smith-Magenis Syndrome biomarker development ($500,500), and paleative care needs in rare pediatric diseases ($771,848). The National Institute of Mental Health supports research on amygdala circuitry during adolescence, paralaminar nucleus function, and transcranial direct current stimulation response prediction. The NHBLI portfolio includes clinical trials on sickle cell vaso-occlusive crisis management using intravenous citrulline, asthma intervention studies addressing health disparities, and research on cardiac drug response in congenital heart disease. The National Institute of Neurological Disorders and Stroke funds epilepsy biomarker studies, traumatic brain injury research in glial cells, and consciousness recovery mechanisms post-cardiac arrest. The National Cancer Institute supports neuroblastoma immunotherapy using natural killer cell exosomes and adoptive T-cell approaches for medulloblastoma. The Defense Health Agency has funded Duchenne muscular dystrophy therapy development and focused ultrasound enhancement of CAR-T cell therapy. The institute also holds a $3.55 million Biomedical Advanced Research and Development Authority (BARDA) contract with the Office of the Assistant Secretary for Preparedness and Response to establish and operate a Special Populations Hub under the BARDA Accelerator Network 2.0 initiative, providing wraparound services for pediatric medical countermeasures.

As a prime recipient, Children's Research Institute leads investigator-initiated research with faculty and clinical staff as principal investigators. As a subrecipient on consortium and cooperative agreement awards, the institute enrolls patients, performs clinical site activities, conducts mechanistic studies, and contributes to data analysis and manuscript preparation. Sub-award roles include participation in multisite clinical trials (low-titer whole blood resuscitation for pediatric trauma, balanced fluids in pediatric sepsis), rare disease consortia (urea cycle disorders, organic acidemias, myelin disorders, osteogenesis imperfecta), and consortium-based research networks (Pediatric Emergency Care Applied Research Network, Children's Oncology Group, pediatric critical care networks). The institute partners with Cincinnati Children's Hospital Medical Center and other pediatric medical centers as consortium members.

Service Contract Inventory data shows minimal federal service contract invoicing; the institute reported no SCI-reportable invoiced revenue on prime contracts in FY2024 and limited sub-engagement across the seven SCI records covering FY2022–FY2024. This reflects the organization's operational model as a research-grant recipient rather than a federal services contractor. SCI data indicate 17.4 FTEs delivered to federal research programs in FY2024 across one prime and five sub SCI records, a trajectory that has grown from 8.1 FTEs in FY2022. The organization does not compete under socioeconomic set-asides; federal funding is awarded on the basis of scientific merit and competitive peer review through NIH and other federal research programs.